What does Sono-Tek Corporation do?
Sono-Tek Corporation designs precision ultrasonic coating systems. High-frequency vibration atomizes liquids into minute droplets that form thin, uniform films at low velocity. The technology is useful when coating thickness, repeatability, material efficiency, or complex geometry matters, and it can reduce overspray, material use, energy consumption, and emissions.
The company reports one operating segment but serves medical, electronics, clean energy, industrial, and research markets. Its equipment portfolio runs from tabletop R&D tools to multi-axis, robotic, OEM, fluxing, and in-line production systems. Customers can validate a process on smaller equipment and later scale it without changing the core coating method.
| Research lens | Sono-Tek answer | Why it matters |
|---|---|---|
| Industry | Precision coating equipment and application engineering | Value comes from specialized process solutions. |
| Customer base | Manufacturers, laboratories, universities, and process-development teams worldwide | Orders span R&D tools through production systems. |
| Geography | Global sales network with testing labs in New York and partner locations abroad | Global reach adds demand and channel risk. |
| Reporting structure | One reportable operating segment | Product and market data drive analysis. |
How does Sono-Tek make money?
Sono-Tek earns most revenue from engineered equipment, supplemented by parts, installation, service, and application support. Pricing is project-based. Customized in-line and multi-axis platforms carry far higher values than nozzles or laboratory tools, making quarterly results sensitive to a few shipment dates. Customer deposits help fund work in process.
From laboratory validation to production equipment
Which product categories matter most?
FY2026 multi-axis sales were $8.06 million, or 39% of revenue. In-line systems contributed $7.07 million, or 34%, after rising 91% on several high-value production shipments. Fluxing generated $0.71 million, OEM $1.21 million, and parts, services, and other revenue $3.86 million. The FY2026 Form 10-K confirms that complete systems now dominate the model.
Which end markets drive Sono-Tek's revenue?
End-market leadership can rotate with a few projects. FY2026 was led by alternative energy at $7.97 million, followed by electronics at $6.29 million and medical at $5.00 million. In Q1 FY2027, medical jumped to $3.95 million, nearly 70% of sales, while alternative energy fell to $0.32 million. These markets behave like project portfolios, not recurring segments.
Why medical became the first-quarter growth engine
market mix
Q1 FY2027 medical growth came from U.S. stent systems and drug-eluting-balloon platforms shipped to the United States, China, and Europe, plus a $0.24 million cardiac-device system for Costa Rica. Higher-value systems and more direct domestic selling also supported gross margin.
Geographic reach changes both growth and margin
Foreign customers supplied 38% of Q1 FY2027 revenue, up from 31%. Overseas partner labs described in the investor overview support local demonstrations, while tariffs, distributor economics, and geopolitics add risk.
What do the latest Sono-Tek results show?
Q1 FY2027 sales rose 10% as medical increased 388%, offsetting a 90% alternative-energy decline. Gross profit rose 21% to $3.21 million and gross margin expanded 500 basis points, although management called the mix unusually favorable.
| Metric | Q1 FY2027 | Q1 FY2026 | Change / interpretation |
|---|---|---|---|
| Net sales | $5.661M | $5.133M | Up 10%; medical offset clean energy. |
| Gross profit | $3.214M | $2.665M | Up 21% on mix and direct sales. |
| Operating expenses | $2.317M | $2.181M | Up 6% on commercial investment. |
| Operating income | $0.897M | $0.483M | Margin rose to 15.8% from 9.4%. |
| Net income | $0.741M | $0.485M | Up 53%; margin reached 13.1%. |
| Operating cash flow | $1.941M | $(0.922)M | Receivable collections drove improvement. |
Why did profitability improve so sharply?
Mix drove the margin. Multi-axis sales rose 206% to $2.08 million, and medical reached nearly 70% of revenue. Selling expense increased 19% to $1.03 million, while R&D declined 8% to $0.62 million. The Q1 FY2027 Form 10-Q shows real operating leverage, not a permanently lower cost base.
What strategic turning points shaped Sono-Tek?
Sono-Tek's history shows a progression from proprietary nozzle to integrated automation. Each milestone widened the addressable market or moved the company closer to production-scale systems, as summarized in the official company history.
-
1975Ultrasonic nozzle invention commercialized. Founder Harvey Berger built the company around atomization technology initially intended to improve fuel efficiency.
-
1980s-90sMedical tubes and circuit-board fluxing prove repeatability. These applications established installed-base credibility and thousands of fluxing-system placements.
-
1998First ISO certification. Formal quality systems improved relevance for regulated and advanced-manufacturing customers; the company now cites ISO 9001:2015 certification.
-
2002Programmable multi-axis systems introduced. Motion control turned the nozzle into a more complete automated coating platform.
-
2020Six-axis robotic platforms launched. The product line expanded toward complex three-dimensional surfaces and higher-end semiconductor and industrial automation.
-
2021Nasdaq uplisting completed. The listing improved public-market visibility and governance expectations for a small-cap industrial technology company.
-
2024-25Leadership succession and operating depth. Steve Harshbarger became CEO in January 2024, while Christopher Coccio moved to Executive Chairman; Chris Cichetti became COO in March 2025.
-
FY2026-27Higher-ASP production systems dominate the narrative. In-line sales rose 91% in FY2026, and Q1 FY2027 medical platforms drove record quarterly margins.
What changed economically?
The current model captures the nozzle, liquid delivery, motion control, software, integration, installation, and process support. This raises selling price and switching costs but requires more working capital and execution discipline.
What gives Sono-Tek a competitive advantage?
Sono-Tek's moat combines patents, trade secrets, more than 2,500 nozzle configurations, application data, and customer-specific recipes. A rival must reproduce both hardware and process know-how.
How durable are the moat components?
Who competes with Sono-Tek?
Competition comes from alternative deposition methods and equipment manufacturers. Buyers compare price, performance, lead time, engineering support, and service. Emerging applications can be less crowded when ultrasonic deposition solves a specific problem.
| Competitive force | Pressure on Sono-Tek | Strategic response |
|---|---|---|
| Alternative deposition methods | Customers may accept a cheaper or faster method if uniformity and overspray are less critical. | Target applications where material savings, complex coverage, or repeatability justify ultrasonic technology. |
| Integrated automation vendors | Larger suppliers can offer broad factory-automation portfolios and global service capacity. | Differentiate through coating science, customization, and faster application development. |
| Ultrasonic nozzle specialists | Comparable atomization hardware could narrow the component advantage. | Bundle nozzle design with recipes, controls, testing labs, and installed-base support. |
| Customer in-house engineering | Large manufacturers may develop or integrate their own coating process. | Become the process partner during R&D so Sono-Tek remains embedded during scale-up. |
How financially strong is Sono-Tek?
At May 31, 2026, current assets were $22.64 million against $5.18 million of current liabilities, producing $17.46 million of working capital and a 4.4-times current ratio. Cash and securities exceeded three times current liabilities. Unused facilities included a $1.50 million revolver and $0.75 million equipment line, giving management flexibility without external debt.
How does cash flow convert from earnings?
Free cash flow equals operating cash flow less equipment and facility purchases. Q1 FY2027 produced about $1.86 million, but receivable collections of $2.09 million and a $1.06 million deposit reduction make annualization inappropriate.
| Balance-sheet item | May 31, 2026 | February 28, 2026 | Interpretation |
|---|---|---|---|
| Cash and equivalents | $8.982M | $7.339M | Increased after strong operating cash flow. |
| Marketable securities | $7.670M | $7.470M | Adds liquidity and interest income. |
| Accounts receivable | $1.265M | $3.351M | Collections explain much of Q1 cash generation. |
| Inventory | $4.063M | $3.923M | Work in process rose for customer requirements. |
| Customer deposits | $2.007M | $3.070M | Deposits declined as completed systems shipped. |
| Debt | $0 | $0 | No interest-bearing borrowings were outstanding. |
Who owns Sono-Tek stock, and how is it governed?
Sono-Tek has one common-stock class, but ownership is concentrated. At May 19, 2026, Emancipation Management, Charles Frumberg, and Circle N Advisors reported shared disposition power over 5.47 million shares, or 34.82%. Two individuals each held nearly 6%, and directors and officers owned 5.57%. A small number of holders can therefore influence elections and strategy.
| Holder / group | Shares | Ownership | Why it matters |
|---|---|---|---|
| Emancipation Management / Charles Frumberg / Circle N Advisors | 5,472,052 | 34.82% | Largest disclosed block; shared disposition power creates substantial voting influence. |
| Dawn Cupero | 924,289 | 5.88% | A second meaningful individual blockholder. |
| V. Adah Nicklin | 915,599 | 5.83% | Another holder above the 5% disclosure threshold. |
| Directors and executive officers as a group | 886,709 | 5.57% | Aligns leadership with equity value, including exercisable options. |
| Executive Chairman Christopher Coccio | 370,673 | 2.35% | Maintains strategic continuity after moving from CEO to Executive Chairman. |
| CEO R. Stephen Harshbarger | 305,521 | 1.94% | Meaningful personal exposure to operating and capital-allocation outcomes. |
What governance signals matter?
The FY2026 10-K lists seven directors and three audit-committee members. Two-year classified terms can slow board turnover. Harshbarger became CEO in January 2024 after joining Sono-Tek in 1993; former CEO Coccio remains Executive Chairman. The governance materials describe risk oversight and committee duties.
What opportunities and risks could change the story?
Growth depends on customer scale-up, medical and semiconductor adoption, clean-energy recovery, and direct sales. Higher-value systems also create concentrated orders, lumpy shipments, and execution risk.
Which risks are most material?
| Risk | Current evidence | Financial line affected | What to monitor |
|---|---|---|---|
| Customer concentration | Two customers generated 53% of Q1 FY2027 sales; one customer generated 28% of FY2026 revenue. | Revenue, backlog, receivables, margin | Order and receivable diversity. |
| Large-order timing | Backlog fell from $9.12M at FY2026 year-end to $7.73M at May 31, 2026 after shipments. | Quarterly revenue and operating leverage | New orders and delivery dates. |
| End-market cyclicality | Alternative-energy sales declined 90% in Q1 FY2027 while medical rose 388%. | Product mix and gross margin | Solar, electrolysis, and fuel-cell orders. |
| Technology and IP | Patents can be challenged or circumvented; alternative coating methods can improve. | Pricing, R&D, market share | System launches and validation. |
| Execution complexity | The business is transitioning toward complete, customized machines and subsystems. | Warranty, labor, working capital, delivery costs | Delivery, warranty, and inventory. |
| Trade and geopolitical exposure | 38% of Q1 FY2027 sales were outside the U.S. and Canada. | Demand, logistics, commissions, input cost | Tariffs and distributor economics. |
The Q1 FY2027 earnings release projected first-half growth but only flat-to-modest full-year growth. Backlog provides visibility, not uniform margin, timing, or cancellation protection.
Which KPIs matter most for Sono-Tek?
Revenue and EPS are insufficient for a customized-equipment business. Backlog conversion, high-value system mix, customer concentration, gross margin, working capital, and R&D commercialization reveal whether growth is durable or project-dependent.
How should backlog be interpreted?
Backlog is not guaranteed revenue: orders may be delayed or cancelled, often with deposits as the main penalty. May 31, 2026 backlog equaled roughly 37% of FY2026 sales. Conversion timing, mix, and replenishment matter more than the ratio alone.
Why does Sono-Tek's business model matter for valuation?
A DCF should treat Sono-Tek as a project-driven manufacturer. Revenue depends on application wins and shipment timing; margin depends on mix and execution; working capital moves with deposits, receivables, and inventory.
| Valuation driver | Current evidence | DCF implication |
|---|---|---|
| Revenue growth | FY2026 sales grew 2%; Q1 FY2027 grew 10%; full-year FY2027 outlook was flat to modest growth. | Use scenarios tied to backlog, medical adoption, and clean energy. |
| Gross margin | 50.5% in FY2026 and 56.8% in Q1 FY2027. | Normalize below Q1 unless favorable mix persists. |
| Operating leverage | Q1 FY2027 operating income rose 86% on 10% revenue growth. | Strong incremental margins still require commercial investment. |
| Reinvestment | FY2026 R&D was $2.55M and capex was $0.22M. | Treat R&D as recurring growth investment. |
| Working capital | Q1 cash flow benefited from $2.09M of receivable collections and used $1.06M of deposits. | Forecast deposits, receivables, and inventory separately. |
| Net cash | $16.65M of cash and securities with no debt at May 31, 2026. | Net cash lowers enterprise value and financing risk. |
| Concentration risk | Two customers supplied 53% of Q1 FY2027 sales. | Concentration supports conservative terminal assumptions. |
What should a normalized model look like?
Model revenue by market, connect production-system mix to margin, preserve R&D and selling investment, normalize working capital, and add net cash separately. Multiple scenarios are preferable.
What is the key takeaway from Sono-Tek analysis?
The weakness is volatility. Two customers supplied 53% of Q1 sales, market leadership rotated sharply, backlog fell after year-end shipments, and full-year guidance remained flat to modest growth. Technological quality does not equal forecast certainty.
Sono-Tek illustrates the move from proprietary component to integrated solution. The decisive questions are repeat medical adoption, clean-energy recovery, backlog replenishment, and sustainable margins without underinvesting. Official filings are available through the annual-report and proxy page.
What should be monitored next?
- Conversion and replenishment of the $7.73 million May 31, 2026 backlog.
- Repeat medical orders for stent and drug-eluting-balloon systems.
- Alternative-energy orders across solar, electrolysis, fuel cells, and carbon capture.
- Gross margin versus 50.5% in FY2026 and 56.8% in Q1 FY2027.
- Customer concentration, accounts-receivable concentration, and the mix of direct versus distributor sales.
- R&D and sales investment needed for scale-up.
- Working capital as large systems move through production.
- Use of net cash for investment, acquisitions, or repurchases.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.